Cover Image

Metastasiertes Prostatakarzinom: Positionspapier zum Einsatz der Chemotherapie = Metastasized prostate cancer : position paper on the use of chemotherapy

Background Antihormonal and cytotoxic therapy options are available for the therapy of metastasized prostate cancer (mPC). Because no comparative studies are available, especially for castration-resistant prostate cancer (mCRCP), it remains unclear which patients will profit best from which therapy....

Full description

Saved in:
Bibliographic Details
Main Authors: Ohlmann, Carsten-Henning (Author) , Duensing, Stefan (Author)
Format: Article (Journal)
Language:German
English
Published: July 2015
In: Der Urologe
Year: 2015, Volume: 54, Issue: 7, Pages: 998-1001
DOI:10.1007/s00120-015-3841-0
Online Access:Verlag, Volltext: http://dx.doi.org/10.1007/s00120-015-3841-0
Verlag, Volltext: https://link.springer.com/article/10.1007/s00120-015-3841-0
Get full text
Author Notes:C.-H. Ohlmann, S. Duensing, R. Eichenauer, F. König, S. Machtens, M. Schostak, C. Thomas, P. Albers

MARC

LEADER 00000caa a2200000 c 4500
001 1556038496
003 DE-627
005 20221117134808.0
007 cr uuu---uuuuu
008 170329s2015 xx |||||o 00| ||ger c
024 7 |a 10.1007/s00120-015-3841-0  |2 doi 
035 |a (DE-627)1556038496 
035 |a (DE-576)486038491 
035 |a (DE-599)BSZ486038491 
035 |a (OCoLC)1340969081 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a ger  |a eng 
084 |a 33  |2 sdnb 
100 1 |a Ohlmann, Carsten-Henning  |e VerfasserIn  |0 (DE-588)1022541129  |0 (DE-627)716997908  |0 (DE-576)361868138  |4 aut 
245 1 0 |a Metastasiertes Prostatakarzinom  |b Positionspapier zum Einsatz der Chemotherapie = Metastasized prostate cancer : position paper on the use of chemotherapy  |c C.-H. Ohlmann, S. Duensing, R. Eichenauer, F. König, S. Machtens, M. Schostak, C. Thomas, P. Albers 
246 3 1 |a Metastasized prostate cancer  |b position paper on the use of chemotherapy 
264 1 |c July 2015 
300 |a 4 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 29.03.2017 
520 |a Background Antihormonal and cytotoxic therapy options are available for the therapy of metastasized prostate cancer (mPC). Because no comparative studies are available, especially for castration-resistant prostate cancer (mCRCP), it remains unclear which patients will profit best from which therapy.Objectives Previous data on the sequence of the various therapy options show that correct selection of the first line therapy for mCRPC can have an influence on the prognosis of the patient. In this position paper the various therapy options are critically illustrated and the clinical and pathohistological criteria for selection of the first line therapy of mCRPC are discussed.Results Molecular markers are an important aid for future patient selection and individualized therapy for optimal use of the available forms of therapy. 
700 1 |a Duensing, Stefan  |d 1967-  |e VerfasserIn  |0 (DE-588)1074044487  |0 (DE-627)830213007  |0 (DE-576)435550098  |4 aut 
773 0 8 |i Enthalten in  |t Der Urologe  |d [Berlin : Springer Medizin, 2005  |g 54(2015), 7, Seite 998-1001  |h Online-Ressource  |w (DE-627)101704192X  |w (DE-600)2925337-8  |w (DE-576)501620842  |7 nnas  |a Metastasiertes Prostatakarzinom Positionspapier zum Einsatz der Chemotherapie = Metastasized prostate cancer : position paper on the use of chemotherapy 
773 1 8 |g volume:54  |g year:2015  |g number:7  |g pages:998-1001  |g extent:4  |a Metastasiertes Prostatakarzinom Positionspapier zum Einsatz der Chemotherapie = Metastasized prostate cancer : position paper on the use of chemotherapy 
856 4 0 |u http://dx.doi.org/10.1007/s00120-015-3841-0  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://link.springer.com/article/10.1007/s00120-015-3841-0  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20170329 
993 |a Article 
994 |a 2015 
998 |g 1074044487  |a Duensing, Stefan  |m 1074044487:Duensing, Stefan  |d 910000  |d 910200  |e 910000PD1074044487  |e 910200PD1074044487  |k 0/910000/  |k 1/910000/910200/  |p 2 
999 |a KXP-PPN1556038496  |e 2962923011 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"July 2015","dateIssuedKey":"2015"}],"language":["ger","eng"],"note":["Gesehen am 29.03.2017"],"title":[{"title":"Metastasiertes Prostatakarzinom","title_sort":"Metastasiertes Prostatakarzinom","subtitle":"Positionspapier zum Einsatz der Chemotherapie = Metastasized prostate cancer : position paper on the use of chemotherapy"}],"recId":"1556038496","titleTranslated":[{"translated":"Metastasized prostate cancer"}],"id":{"doi":["10.1007/s00120-015-3841-0"],"eki":["1556038496"]},"name":{"displayForm":["C.-H. Ohlmann, S. Duensing, R. Eichenauer, F. König, S. Machtens, M. Schostak, C. Thomas, P. Albers"]},"physDesc":[{"extent":"4 S."}],"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Springer Medizin","dateIssuedDisp":"[2005-2022]","publisherPlace":"[Berlin ; Heidelberg ; New York]"}],"disp":"Metastasiertes Prostatakarzinom Positionspapier zum Einsatz der Chemotherapie = Metastasized prostate cancer : position paper on the use of chemotherapyDer Urologe","language":["ger"],"part":{"extent":"4","year":"2015","issue":"7","volume":"54","text":"54(2015), 7, Seite 998-1001","pages":"998-1001"},"note":["Gesehen am 05.07.2022"],"title":[{"title":"Der Urologe","title_sort":"Urologe"}],"recId":"101704192X","id":{"zdb":["2925337-8"],"eki":["101704192X"]},"name":{"displayForm":["Deutsche Gesellschaft für Urologie"]},"pubHistory":["Volume 44, issue 7 (July 2005)-volume 61, issue 5 (May 2022)"],"physDesc":[{"extent":"Online-Ressource"}],"corporate":[{"display":"Deutsche Gesellschaft für Urologie","role":"isb"}]}],"person":[{"family":"Ohlmann","role":"aut","given":"Carsten-Henning","display":"Ohlmann, Carsten-Henning"},{"role":"aut","family":"Duensing","given":"Stefan","display":"Duensing, Stefan"}]} 
SRT |a OHLMANNCARMETASTASIE2015 

Similar Items